Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 27329844
Smith AM, et al. (2016) Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. Oncotarget 7, 47465-47478 27329844
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T308-p - Akt1 (human)
Modsite: kDGAtMKtFCGtPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), MV4-11 (macrophage)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
fingolimod no change compared to control
FL increase

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), MV4-11 (macrophage)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
fingolimod decrease
FL increase

Y221-p - JAK2 (human)
Modsite: IRAKIQDyHILTRKR SwissProt Entrez-Gene
Orthologous residues
JAK2 (human): Y221‑p, JAK2 (mouse): Y221‑p, JAK2 (rat): Y221‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), MV4-11 (macrophage)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
FL increase
fingolimod no change compared to control

Y307-p - PPP2CA (human)
Modsite: VTRRtPDyFl_____ SwissProt Entrez-Gene
Orthologous residues
PPP2CA (human): Y307‑p, PPP2CA iso2 (human): Y253‑p, PPP2CA (mouse): Y307‑p, PPP2CA (rat): Y307‑p, PPP2CA (pig): Y307‑p, PPP2CA (cow): Y307‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), MV4-11 (macrophage)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
fingolimod no change compared to control

Y705-p - STAT3 (human)
Modsite: DPGsAAPyLKtKFIC SwissProt Entrez-Gene
Orthologous residues
STAT3 (human): Y705‑p, STAT3 iso2 (human): Y704‑p, STAT3 iso3 (human): Y705‑p, STAT3 (mouse): Y705‑p, STAT3 iso2 (mouse): Y705‑p, STAT3 iso3 (mouse): Y704‑p, STAT3 (rat): Y705‑p, STAT3 (cow): Y705‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), MV4-11 (macrophage)
Cellular systems studied:  cell lines
Species studied:  mouse

Y694-p - STAT5A (human)
Modsite: LAkAVDGyVkPQIkQ SwissProt Entrez-Gene
Orthologous residues
STAT5A (human): Y694‑p, STAT5A (mouse): Y694‑p, STAT5A iso2 (mouse): , STAT5A (rat): Y694‑p, STAT5A (fruit fly): Y711‑p, STAT5A (sheep): Y694‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  leukemia, acute myelogenous leukemia
Relevant cell lines - cell types - tissues:  BaF3 ('B lymphocyte, precursor'), MV4-11 (macrophage)
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
fingolimod increase